Targeted pharmacotherapy for ischemia reperfusion injury in acute myocardial infarction

References

• Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357:1121–1135.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Muntner P, Alonso A, et al. American heart association council on epidemiology and prevention statistics committee and stroke statistics subcommittee. heart disease and stroke statistics-2019 update: a report from the American heart association. Circulation. 2019;139:e56–e528.
   PubMed Web of Science ®Google Scholar
• Hausenloy D, Yellon D. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest. 2013;123:92–100.
   PubMed Web of Science ®Google Scholar
• Hausenloy DJ, Barrabes JA, Botker HE, et al. Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery. Basic Res Cardiol. 2016;111:170.
   Web of Science ®Google Scholar
• Gurbel PA, Anderson RD, MacCord CS, et al. Arterial diastolic pressure augmentation by intra-aortic balloon counterpulsation enhances the onset of coronary artery reperfusion by thrombolytic therapy. Circulation. 1994;89:361–365.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, MacCord CS, Anderson RD, et al. a canine model of acute coronary artery thrombosis for the evaluation of reperfusion strategies. Cardiology. 1994;84:1–8.
   PubMed Web of Science ®Google Scholar
• Davidson SM, Ferdinandy P, Andreadou I, et al. Multitarget strategies to reduce myocardial ischemia/reperfusion injury: JACC review topic of the week. J Am Coll Cardiol. 2019;73:89–99.
   PubMed Web of Science ®Google Scholar
• Ibáñez B, Heusch G, Ovize M, et al., Evolving therapies for myocardial ischemia/reperfusion injury. Journal of the American College of Cardiology. 2015; 65(14):1454–1471.
   PubMed Web of Science ®Google Scholar
• Piper HM, García-Dorado D, Ovize M. a fresh look at reperfusion injury. Cardiovasc Res. 1998;38:291–300.
   PubMed Web of Science ®Google Scholar
• Veinot JP, Gattinger DA, Fliss H. Early apoptosis in human myocardial infarcts. Hum Pathol. 1997;28:485–492.
   PubMed Web of Science ®Google Scholar
• Zweier JL, Talukder MA. The role of oxidants and free radicals in reperfusion injury. Cardiovasc Res. 2006;70:181–190.
   PubMed Web of Science ®Google Scholar
• Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation. 2000;101:570–580.
   PubMed Web of Science ®Google Scholar
• Liu Y, Gao XM, Fang L, et al. Novel role of platelets in mediating inflammatory responses and ventricular rupture or remodeling following myocardial infarction. Arterioscler Thromb Vasc Biol. 2011;31:834–841.
   PubMed Web of Science ®Google Scholar
• Ren F, Mu N, Zhang X, et al. Increased platelet-leukocyte aggregates are associated with myocardial no-reflow in patients with ST elevation myocardial infarction. Am J Med Sci. 2016;352:261–266.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Serebruany VL, Komiathy SF, et al. Pretreatment with an inhibitor of mac-1 alters regional and systemic platelet function during ischemia-reperfusion in swine. Pharmacology. 1996;53:79–86.
   PubMed Web of Science ®Google Scholar
• Mirabet M, Garcia-Dorado D, Inserte J, et al. Platelets activated by transient coronary occlusion exacerbate ischemia-reperfusion injury in rat hearts. Am J Physiol Heart Circ Physiol. 2002;283:H1134–41.
   PubMed Web of Science ®Google Scholar
• Duerschmied D, Suidan GL, Demers M, et al. Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice. Blood. 2013;121:1008–1015.
   PubMed Web of Science ®Google Scholar
• Schuhmann MK, Guthmann J, Stoll G, et al. Blocking of platelet glycoprotein receptor Ib reduces “thrombo-inflammation” in mice with acute ischemic stroke. J Neuroinflammation. 2017;14:18.
   PubMed Web of Science ®Google Scholar
• von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res. 2007;100:27–40.
   PubMed Web of Science ®Google Scholar
• Boilard E, Nigrovic PA, Larabee K, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science. 2010;327:580–583.
   PubMed Web of Science ®Google Scholar
• Huo Y, Schober a, Forlow SB, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med. 2003;9:61–67.
   PubMed Web of Science ®Google Scholar
• Dong JW, Vallejo JG, Tzeng HP, et al. Innate immunity mediates myocardial preconditioning through Toll-like receptor 2 and TIRAP-dependent signaling pathways. Am J Physiol Heart Circ Physiol. 2010;298:H1079–H1087.
   PubMed Web of Science ®Google Scholar
• Horckmans M, Ring L, Duchene J, et al. Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype. Eur Heart J. 2017;38:187–197.
   PubMed Web of Science ®Google Scholar
• Prabhu SD, Frangogiannis NG. The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. Circ Res. 2016;119:91–112.
   PubMed Web of Science ®Google Scholar
• Murphy CT, Peers SH, Forder RA, et al. Evidence for the presence and location of annexins in human platelets. Biochem Biophys Res Commun. 1992;189:1739–1746.
   PubMed Web of Science ®Google Scholar
• Lannan KL, Spinelli SL, Blumberg N, et al. Maresin 1 induces a novel pro-resolving phenotype in human platelets. J Thromb Haemost. 2017;15:802–813.
   PubMed Web of Science ®Google Scholar
• Pierce GF, Mustoe TA, Lingelbach J, et al. Platelet derived growth factor and transforming growth factor-beta enhance tissue repair activities by unique mechanisms. J Cell Biol. 1989;109:429–440.
   PubMed Web of Science ®Google Scholar
• Yabanoglu S, Akkiki M, Seguelas MH, et al. Platelet derived serotonin drives the activation of rat cardiac fibroblasts by 5-HT receptors. J Mol Cell Cardiol. 2009;46:518–525.
   PubMed Web of Science ®Google Scholar
• Huang C, Xiao X, Yang Y, et al. MicroRNA-101 attenuates pulmonary fibrosis by inhibiting fibroblast proliferation and activation. J Biol Chem. 2015;292:16420–16439.
   Web of Science ®Google Scholar
• Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. Nature. 2011;469:336–342.
   PubMed Web of Science ®Google Scholar
• Ziegler M, Wang X, Peter K. Platelets in cardiac ischaemia/reperfusion injury: a promising therapeutic target. Cardiovasc Res. 2019;115:1178–1188.
   PubMed Web of Science ®Google Scholar
• Husain S, Andrews NP, Mulcahy D, et al. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation. 1998;97:716–720.
   PubMed Web of Science ®Google Scholar
• Fu L-W, Longhurst JC. Role of activated platelets in excitation of cardiac afferents during myocardial ischemia in cats. Am J Physiol Heart Circ Physiol. 2002;282:H100–H109.
   PubMed Web of Science ®Google Scholar
• Klein HH, Pich S, Lindert S, et al. Treatment of reperfusion injury with intracoronary calcium channel antagonists and reduced coronary free calcium concentration in regionally ischemic, reperfused porcine hearts. J Am Coll Cardiol. 1989;13:1395–1401.
   PubMed Web of Science ®Google Scholar
• Gross ER, Hsu AK, Gross GJ. Acute methadone treatment reduces myocardial infarct size via the delta-opioid receptor in rats during reperfusion. Anesth Analg. 2009;109:1395–1402.
   PubMed Web of Science ®Google Scholar
• Xu Y, Huo Y, Toufektsian MC, et al. Activated platelets contribute importantly to myocardial reperfusion injury. Am J Physiol Heart Circ Physiol. 2006;290:H692–H699.
   PubMed Web of Science ®Google Scholar
• Barrabés JA, Garcia-Dorado D, Mirabet M, et al. Antagonism of selectin function attenuates microvascular platelet deposition and platelet-mediated myocardial injury after transient ischemia. J Am Coll Cardiol. 2005;45:293–299.
   PubMed Web of Science ®Google Scholar
• Khandoga a, Biberthaler P, Enders G, et al. P-selectin mediates platelet-endothelial cell interactions and reperfusion injury in the mouse liver in vivo. Shock. 2002;18:529–535.
   PubMed Web of Science ®Google Scholar
• Mertens P, Maes a, Nuyts J, et al. PSALM investigators. Recombinant P-selectin glycoprotein ligand-immunoglobulin, a P-selectin antagonist, as an adjunct to thrombolysis in acute myocardial infarction. The P-selectin antagonist limiting myonecrosis (PSALM) trial. Am Heart J. 2006;152:125.e1–8.
   PubMed Web of Science ®Google Scholar
• Tardif JC, Tanguay JF, Wright SR, et al. Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. J Am Coll Cardiol. 2013;61:2048–2055.
   PubMed Web of Science ®Google Scholar
• Stähli BE, Gebhard C, Duchatelle V, et al. Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention according to timing of infusion: insights from the SELECT-ACS trial. J Am Heart Assoc. 2016;5:e004255.
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Herzog WR, Gurbel PA. Serial changes of natural antithrombotics during myocardial ischemia-reperfusion in swine. Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor. Blood Coagul Fibrinolysis. 1996;7:632–640.
   PubMed Web of Science ®Google Scholar
• Faxon D, Gibbons R, Chronos N, et al. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT MI study. J Am Coll Cardiol. 2002;40:1199–1204.
   PubMed Web of Science ®Google Scholar
• Baran KW, Nguyen M, McKendall GR, et al. Double-blind, randomized trial of an anti-CD 18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation. 2001;104:2778–2883.
   PubMed Web of Science ®Google Scholar
• Ritschel VN, Seljeflot I, Arnesen H, et al. Circulating levels of IL-6 receptor and gp130 and long-term clinical outcomes in ST-elevation myocardial infarction. J Am Heart Assoc. 2016;5:e003014.
   PubMed Web of Science ®Google Scholar
• Kobara M, Noda K, Kitamura M, et al. Antibody against interleukin-6 receptor attenuates left ventricular remodelling after myocardial infarction in mice. Cardiovasc Res. 2010;87:424–430.
   PubMed Web of Science ®Google Scholar
• Kleveland O, Kunszt G, Bratlie M, et al. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. Eur Heart J. 2016;37(30):2406–2413.
   PubMed Web of Science ®Google Scholar
• Anstensrud AK, Woxholt S, Sharma K, et al. Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI). Open Heart. 2019;6:e001108.
   PubMed Web of Science ®Google Scholar
• Abbate a, Van Tassell BW, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia commonwealth University-Anakinra remodeling trial (2) (VCU-ART2) pilot study]. Am J Cardiol. 2013;111(10):1394–1400.
   PubMed Web of Science ®Google Scholar
• Van Tassell BW, Lipinski MJ, Appleton D, et al. Rationale and design of the Virginia commonwealth University-Anakinra remodeling Trial-3(VCU-ART3): a randomized, placebo-controlled, double-blinded, multicenter study. Clin Cardiol. 2018;41:1004–1008.
   PubMed Web of Science ®Google Scholar
• Granger CB, Mahaffey KW, Weaver WD, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the complement inhibition in myocardial infarction treated with angioplasty (CoMMA) trial. Circulation. 2003;108:1184–1190.
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Granger CB, Nicolau JC, et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the complement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation. 2003;108:1176–1183.
   PubMed Web of Science ®Google Scholar
• Nidorf SM, Eikelboom JW, Thompson PL. Targeting cholesterol crystal-induced inflammation for the secondary prevention of cardiovascular disease. J Cardiovasc Pharmacol Ther. 2014;19:45–52.
   PubMed Web of Science ®Google Scholar
• Shah B, Allen N, Harchandani B, et al. Effect of colchicine on platelet-platelet and platelet-leukocyte interactions: a pilot study in healthy subjects. Inflammation. 2016;39:182–189.
   PubMed Web of Science ®Google Scholar
• Nidorf SM, Thompson PL. Why colchicine should be considered for secondary prevention of atherosclerosis: an overview. Clin Ther. 2019;41:41–48.
   PubMed Web of Science ®Google Scholar
• Deftereos S, Giannopoulos G, Angelidis C, et al. Anti-Inflammatory treatment with colchicine in acute myocardial infarction: a pilot study. Circulation. 2015;132:1395–1403.
   PubMed Web of Science ®Google Scholar
• Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497–2505.
   PubMed Web of Science ®Google Scholar
• Colchicine in Percutaneous Coronary Intervention. 2019 Nov 17. Presented by: Binita Shah, MD, MS (NYU School of Medicine), at AHA Scientific Sessions 2019, Philadelphia, PA.
   Google Scholar
• Colchicine and spironolactone in patients with STEMI/SYNERGY stent registry (CLEAR-SYNERGY).[cited 2020 Feb 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03048825
   Google Scholar
• Ishii H, Ichimiya S, Kanashiro M, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation. 2005;112:1284–1288.
   PubMed Web of Science ®Google Scholar
• Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007;370:1483–1493.
   PubMed Web of Science ®Google Scholar
• Yang XM, Liu Y, Cui L, et al. Platelet P2Y blockers confer direct postconditioning-like protection in reperfused rabbit hearts. J Cardiovasc Pharmacol Ther. 2013;18:251–262.
   PubMed Web of Science ®Google Scholar
• Roubille F, Lairez O, Mewton N, et al. Cardioprotection by clopidogrel in acute ST-elevated myocardial infarction patients: a retrospective analysis. Basic Res Cardiol. 2012;107:275.
   PubMed Web of Science ®Google Scholar
• Park Y, Tantry US, Koh JS, et al. Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction: the REMODELING trial. Thromb Haemost. 2017;117:911–922.
   PubMed Web of Science ®Google Scholar
• Armstrong D, Summers C, Ewart L, et al. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther. 2014;19:209–219.
   PubMed Web of Science ®Google Scholar
• Vilahur G, Gutiérrez M, Casani L, et al. Protective effects of ticagrelor on myocardial injury after infarction. Circulation. 2016;134:1708–1719.
   PubMedGoogle Scholar
• Yang XM, Cui L, Alhammouri a, et al. Triple therapy greatly increases myocardial salvage during ischemia/reperfusion in the in situ rat heart. Cardiovasc Drugs Ther. 2013;27:403–412.
   PubMed Web of Science ®Google Scholar
• Nanhwan MK, Ling S, Kodakandla M, et al. Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect. Arterioscler Thromb Vasc Biol. 2014;34:2078–2085.
   PubMed Web of Science ®Google Scholar
• Ye Y, Birnbaum GD, Perez-Polo JR, et al. Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction. Arterioscler Thromb Vasc Biol. 2015;35:1805–1814.
   PubMed Web of Science ®Google Scholar
• Liu X, Gu Y, Liu Y, et al. Ticagrelor attenuates myocardial ischaemia-reperfusion injury possibly through downregulating galectin-3 expression in the infarct area of rats. Br J Clin Pharmacol. 2018;84:1180–1186.
   PubMed Web of Science ®Google Scholar
• Liu X, Wang Y, Zhang M, et al. Ticagrelor reduces ischemia-reperfusion injury through the NF-κB-dependent pathway in rats. J Cardiovasc Pharmacol. 2019;74:13–19.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj a, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep;361(11):1045–1057.
   PubMed Web of Science ®Google Scholar
• Park Y, Choi SW, Oh JH, et al. HEALING-AMI trial investigators. rationale and design of the high platelet inhibition with ticagrelor to improve left ventricular remodeling in patients with ST-segment elevation myocardial infarction (HEALING-AMI) trial. Korean Circulation Journal. 2019;49(7):586–599.
   PubMed Web of Science ®Google Scholar
• Yang X-M, Liu Y, Cui L, et al. Platelet P2Y 12 blockers confer direct postconditioning-like protection in reperfused rabbit hearts. J Cardiovasc Pharmacol Ther. 2013;18(3):251–262.
   PubMed Web of Science ®Google Scholar
• Yang X-M, Liu Y, Cui L, et al. Two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts. Cardiovasc Drugs Ther. 2013;27(2):109–115.
   PubMed Web of Science ®Google Scholar
• Bell RM, Sivaraman V, Kunuthur SP, et al. Cardioprotective properties of the platelet P2Y12 receptor inhibitor, cangrelor: protective in diabetics and reliant upon the presence of blood. Cardiovasc Drugs Ther. 2015;29(5):415–418.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Stone GW, Mahaffey KW, et al. CHAMPION PHOENIX investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368(14):1303–1313.
   PubMed Web of Science ®Google Scholar
• Tantry U, Chaudhary R, Kubica J, et al. Cangrelor for the treatment of patients with arterial thrombosis. Expert Opin Pharmacother. 2018;19(12):1389–1398.
   PubMed Web of Science ®Google Scholar
• Bulluck H, Chan MHH, Bryant JA, et al. Platelet inhibition to target reperfusion injury trial: rationale and study design. Clin Cardiol. 2019;42(1):1–5.
   Web of Science ®Google Scholar
• Kunichika H, Ben-Yehuda O, Lafitte S, et al. Effects of glycoprotein IIb/IIIa inhibition on microvascular flow after coronary reperfusion. a quantitative myocardial contrast echocardiography study. J Am Coll Cardiol. 2004;43(2):276–283.
   PubMed Web of Science ®Google Scholar
• Kupatt C, Wichels R, Horstkotte J, et al. Molecular mechanisms of platelet-mediated leukocyte recruitment during myocardial reperfusion. J Leukoc Biol. 2002;72(3):455–461.
   PubMed Web of Science ®Google Scholar
• Ziegler M, Wang X, Lim B, et al. Platelet-targeted delivery of peripheral blood mononuclear cells to the ischemic heart restores cardiac function after ischemia-reperfusion injury. Theranostics. 2017;7(13):3192–3206.
   PubMed Web of Science ®Google Scholar
• Ziegler M, Haigh K, Nguyen T, et al. The pulmonary microvasculature entraps induced vascular progenitor cells (iVPCs) systemically delivered after cardiac ischemia-reperfusion injury: indication for preservation of heart function via paracrine effects beyond engraftment. Microcirculation. 2019;26(2):e12493.
   PubMed Web of Science ®Google Scholar
• Schönberger T, Ziegler M, Borst O, et al. The dimeric platelet collagen receptor GPVI-Fc reduces platelet adhesion to activated endothelium and preserves myocardial function after transient ischemia in mice. Am J Physiol Cell Physiol. 2012;303(7):C757–C766.
   PubMed Web of Science ®Google Scholar
• Rout a, Sukhi a, Chaudhary R, et al. Investigational drugs in phase II clinical trials for acute coronary syndromes. Expert Opin Investig Drugs. 2020;29(1):33–47.
   PubMed Web of Science ®Google Scholar
• Pachel C, Mathes D, Arias-Loza a-P, et al. Inhibition of platelet GPVI protects against myocardial ischemia–reperfusion injury. Arterioscler Thromb Vasc Biol. 2016;36(4):629–635.
   PubMed Web of Science ®Google Scholar
• Sekili S, Jeroudi MO, Tang X-L, et al. Effect of adenosine on myocardial ‘stunning’ in the dog. Circ Res. 1995;76(1):82–94.
   PubMed Web of Science ®Google Scholar
• Sharma V, Bell RM, Yellon DM. Targeting reperfusion injury in acute myocardial infarction: a review of reperfusion injury pharmacotherapy. Expert Opin Pharmacother. 2012;13(8):1153–1175.
   PubMed Web of Science ®Google Scholar
• Marzilli M, Orsini E, Marraccini P, et al. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation. 2000;101(18):2154–2159.
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the acute myocardial infarction STudy of ADenosine (AMISTAD) trial. Journal of the American College of Cardiology. 1999;34(6):1711–1720.
   PubMed Web of Science ®Google Scholar
• Ross AM, Gibbons RJ, Stone GW, et al. AMISTAD-II investigators. a randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol. 2005;45(11):1775–1780.
   PubMed Web of Science ®Google Scholar
• Kloner RA, Forman MB, Gibbons RJ, et al. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J. 2006;27(20):2400–2405.
   PubMed Web of Science ®Google Scholar
• Quintana M, Hjemdahl P, Sollevi a, et al. Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis, results of the ATTenuation by Adenosine of Cardiac Complications (ATTACC) study. Eur J Clin Pharmacol. 2003;59:1–9.
   PubMed Web of Science ®Google Scholar
• Quintana M, Kahan T, Hjemdahl P. Pharmacological prevention of reperfusion injury in acute myocardial infarction. a potential role for adenosine as a therapeutic agent. Am J Cardiovasc Drugs. 2004;4(3):159–167.
   PubMedGoogle Scholar
• Kopecky SL, Aviles RJ, Bell MR, et al. a randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 delivery for myocardial infarction reduction) study. Am Heart J. 2003;146(1):146–152.
   PubMed Web of Science ®Google Scholar
• Nazir SA, Khan JN, Mahmoud IZ, et al. The REFLO-STEMI (Reperfusion facilitated by local adjunctive therapy in ST-Elevation myocardial infarction) trial: a randomised controlled trial comparing intracoronary administration of adenosine or sodium nitroprusside with control for attenuation of microvascular obstruction during primary percutaneous coronary intervention. Southampton (UK): NIHR Journals Library; 2016 Dec.
   Google Scholar
• Audia JP, Yang X-M, Crockett ES, et al. Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y12 receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function. Basic Res Cardiol. 2018;113(5):32.
   PubMed Web of Science ®Google Scholar
• Spath NB, Mills NL, Cruden NL. Novel cardioprotective and regenerative therapies in acute myocardial infarction: a review of recent and ongoing clinical trials. Future Cardiology. 2016;12(6):655–672.
   PubMed Web of Science ®Google Scholar
• Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res. 2004;61:448–460.
   PubMed Web of Science ®Google Scholar
• Hausenloy DJ, Tsang a, Mocanu MM, et al. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol. 2005;288:H971–H976.
   PubMed Web of Science ®Google Scholar
• Davidson SM, Hausenloy D, Duchen MR, et al. Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. Int J Biochem Cell Biol. 2006;38:414–419.
   PubMed Web of Science ®Google Scholar
• Rossello X. Yellon DM.The RISK pathway and beyond. Basic Res Cardiol. 2017;113:2.
   PubMed Web of Science ®Google Scholar
• Jeon SM. Regulation and function of AMPK in physiology and diseases. Exp Mol Med. 2016;48:e245.
   PubMed Web of Science ®Google Scholar
• Zhang P, Liu X, Huang G, et al. Barbaloin pretreatment attenuates myocardial ischemia-reperfusion injury via activation of AMPK. Biochem Biophys Res Commun. 2017;490:1215‐1220.
   Web of Science ®Google Scholar
• Ding M, Wang Y, Sun D, et al. Punicalagin pretreatment attenuates myocardial ischemia-reperfusion injury via activation of AMPK. Am J Chin Med. 2017;45:53‐66.
   Web of Science ®Google Scholar
• Shibata R, Sato K, Pimentel DR, et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med. 2005;11:1096‐1103.
   PubMed Web of Science ®Google Scholar
• Hadebe N, Cour M, Lecour S. The SAFE pathway for cardioprotection: is this a promising target? Basic Res Cardiol. 2018;113:9.
   PubMed Web of Science ®Google Scholar
• Yang X, Yue R, Zhang J, et al. Gastrin protects against myocardial ischemia/reperfusion injury via activation of RISK (reperfusion injury salvage kinase) and SAFE (Survivor activating factor enhancement) pathways. J Am Heart Assoc. 2018;7:14.
   Web of Science ®Google Scholar
• Halestrap AP, Pasdois P. The role of the mitochondrial permeability transition pore in heart disease. Biochim Biophys Acta. 2009;1787:1402–1415.
   PubMed Web of Science ®Google Scholar
• Ong SB, Samangouei P, Kalkhoran SB, et al. The mitochondrial permeability transition pore and its role in myocardial ischemia reperfusion injury. J Mol Cell Cardiol. 2015;78:23–34.
   PubMed Web of Science ®Google Scholar
• Cung TT, Morel O, Cayla G, et al. Cyclosporine before PCI in patients with acute myocardial infarction. N Engl J Med. 2015 Sep;10(373):1021–1031.
   Google Scholar
• Lincoff AM, Roe M, Aylward P, et al. PROTECTION AMI investigators. Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI randomized controlled trial. Eur Heart J. 2014;35:2516–2523.
   PubMed Web of Science ®Google Scholar
• Gibson CM, Giugliano RP, Kloner RA, et al. EMBRACE STEMI study: a phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-on reperfusion injury in patients undergoing primary percutaneous coronary intervention. Eur Heart J. 2016;37:1296–1303.
   PubMed Web of Science ®Google Scholar
• Karbowski M, Youle RJ. Dynamics of mitochondrial morphology in healthy cells and during apoptosis. Cell Death Differ. 2003;10:870‐880.
   Web of Science ®Google Scholar
• Ong SB, Subrayan S, Lim SY, et al. Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation. 2010;121:2012‐2022.
   Web of Science ®Google Scholar
• Wu D, Dasgupta a, Chen KH, et al. Identification of novel dynamin-related protein 1 (Drp1) GTPase inhibitors: therapeutic potential of Drpitor1 and Drpitor1a in cancer and cardiac ischemia-reperfusion injury. Faseb J. 2020;34:1447‐1464.
   Web of Science ®Google Scholar
• Maneechote C, Palee S, Kerdphoo S, et al. Differential temporal inhibition of mitochondrial fission by Mdivi-1 exerts effective cardioprotection in cardiac ischemia/reperfusion injury. Clin Sci (Lond). 2018;132:1669‐1683.
   PubMed Web of Science ®Google Scholar
• Maneechote C, Palee S, Kerdphoo S, et al. Balancing mitochondrial dynamics via increasing mitochondrial fusion attenuates infarct size and left ventricular dysfunction in rats with cardiac ischemia/reperfusion injury. Clin Sci (Lond). 2019;133:497‐513.
   Web of Science ®Google Scholar
• Cooper HA, Eguchi S. Inhibition of mitochondrial fission as a novel therapeutic strategy to reduce mortality upon myocardial infarction. Clin Sci (Lond). 2018;132:2163‐2167.
   PubMed Web of Science ®Google Scholar
• Xue W, Wang X, Tang H, et al. Vitexin attenuates myocardial ischemia/reperfusion injury in rats by regulating mitochondrial dysfunction induced by mitochondrial dynamics imbalance. Biomed Pharmacother. 2020;124:109849.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zhang X, Luan J, et al. Shenxian-Shengmai oral liquid reduces myocardial oxidative stress and protects myocardium from ischemia-reperfusion injury. Cell Physiol Biochem. 2018;48:2503‐2516.
   Google Scholar
• Dong G, Chen T, Ren X, et al. Rg1 prevents myocardial hypoxia/reoxygenation injury by regulating mitochondrial dynamics imbalance via modulation of glutamate dehydrogenase and mitofusin 2. Mitochondrion. 2016;26:7‐18.
   Web of Science ®Google Scholar
• K) Li J, Hu HP, Li Y, Shao W, Zhang JZ, Wang LM. Influences of remifentanil on myocardial ischemia-reperfusion injury and the expressions of Bax and Bcl-2. in rats. Eur Rev Med Pharmacol Sci. 2018;22:8951‐8960.
   Google Scholar
• Wang L, Gill R, Pedersen TL, et al. Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. J Lipid Res. 2009;50:204–213.
   PubMed Web of Science ®Google Scholar
• Olshan DS, DJ R. Angiopoietin-like protein 4: a therapeutic target for triglycerides and coronary disease? J Clin Lipidol. 2018;12:583–587.
   PubMed Web of Science ®Google Scholar
• Bouleti C, Monnot C, Germain S. ANGPTL4, a multifaceted protein at the cross-talk between metabolism and cardiovascular disorders. Int J Cardiol. 2018;256:2.
   PubMed Web of Science ®Google Scholar
• Lafferty MJ, Bradford KC, Erie DA, et al. Angiopoietin-like protein 4 inhibition of lipoprotein lipase: evidence for reversible complex formation. J Biol Chem. 2013 Oct 4;288:28524–28534.
   PubMed Web of Science ®Google Scholar
• Cho DI, Kang HJ, Jeon JH, et al. Antiinflammatory activity of ANGPTL4 facilitates macrophage polarization to induce cardiac repair. JCI Insight. 2019;4:pii:125437.
   Web of Science ®Google Scholar
• Dewey FE, Gusarova V, O’Dushlaine C, et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N Engl J Med. 2016;374:1123–1133.
   PubMed Web of Science ®Google Scholar
• Kass DA, Champion HC, Beavo JA. Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res. 2007;101:1084–1095.
   PubMed Web of Science ®Google Scholar
• Korkmaz-Icöz S, Radovits T, Szabó G. Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure. Br J Pharmacol. 2018;175:223–231.
   PubMed Web of Science ®Google Scholar
• Salloum FN, Chau VQ, Hoke NN, et al. Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein-kinase g-dependent generation of hydrogen sulfide. Circulation. 2009;120:S31–S36.
   PubMedGoogle Scholar
• Anderson SG, Hutchings DC, Woodward M, et al. Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. Heart. 2016;102:1750–1756.
   PubMed Web of Science ®Google Scholar
• Reiter RJ, Tan DX, Galano a. Melatonin: exceeding expectations. Physiology (Bethesda). 2014;29:325–333.
   PubMed Web of Science ®Google Scholar
• Reiter RJ, Tan DX, Gitto E, et al. Pharmacological utility of melatonin in reducing oxidative cellular and molecular damage. Pol J Pharmacol. 2004;56:159–170.
   PubMedGoogle Scholar
• Yu L, Gong B, Duan W, et al. Melatonin ameliorates myocardial ischemia/reperfusion injury in type 1 diabetic rats by preserving mitochondrial function: role of AMPK-PGC-1α-SIRT3 signaling. Sci Rep. 2017;7:41337.
   PubMed Web of Science ®Google Scholar
• Dominguez-Rodriguez a, Abreu-Gonzalez P, de la Torre-hernandez JM, et al. Effect of intravenous and intracoronary melatonin as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: results of the melatonin adjunct in the acute myocaRdial Infarction treated with Angioplasty trial. J Pineal Res. 2017;62:e12374.
   PubMed Web of Science ®Google Scholar
• Dominguez-Rodriguez a, Abreu-Gonzalez P, de la Torre-hernandez JM, et al. Usefulness of early treatment with melatonin to reduce infarct size in patients with ST-segment elevation myocardial infarction receiving percutaneous coronary intervention (from the melatonin adjunct in the acute myocardial infarction treated with angioplasty trial). Am J Cardiol. 2017;120:522‐526.
   PubMed Web of Science ®Google Scholar
• Hausenloy DJ, Garcia-Dorado D, Erik Bøtker H, et al. Melatonin as a cardioprotective therapy following ST-segment elevation myocardial infarction: is it really promising? Reply. Cardiovasc Res. 2017;113:1418‐1419.
   Web of Science ®Google Scholar